We are excited to spread the word about a potentially groundbreaking study to help advance the future of postpartum mental health care through the use of psychedelics.
RECONNECT is a Phase 2 clinical trial led by Reunion Neuroscience evaluating a next-generation, fast-acting treatment with the potential to make a significant impact on women affected by postpartum depression (PPD).
Watch the replay with M.O.M. founder Tracey Tee and Reunion's Sr. Director of Clinical Operations, Kimberly Jett as they break down important details about what this study is all about, timelines, and who is eligible.
🦋 Could psychedelics be the breakthrough moms have been waiting for?
Postpartum depression (PPD) affects 1 in 5 mothers, yet treatment options remain limited. Traditional antidepressants often take weeks to work—if they work at all—and many moms face barriers like stigma, cost, and concerns about breastfeeding. But what if there was a faster, more effective way to heal?
That’s where Reunion Neuroscience comes in. I recently sat down with Kimberly Jett, Senior Director of Clinical Operations at Reunion Neuroscience, for a Q&A about their groundbreaking Phase 2 clinical trial on RE 104—a novel psychedelic compound designed to treat postpartum depression in a single session.
👉 Could RE 104 revolutionize PPD treatment? Here’s what you need to know.
What is RE 104?
RE 104 is a fast-acting, synthetic psychedelic similar in structure to psilocybin (the active ingredient in magic mushrooms), but with a shorter duration—about 3.5 hours instead of 6-8 hours. Delivered via a subcutaneous injection (think a flu shot), it offers a controlled and predictable psychedelic experience, reducing concerns about variability in dosing.
Why is this exciting?
Unlike traditional SSRIs, which require daily use and take weeks to build up in the system, RE 104 may work in just one session, with lasting benefits for postpartum depression.
❓Why Psychedelics for Postpartum Depression?
Research has shown that psychedelics like psilocybin can promote neuroplasticity, helping the brain heal by rewiring thought patterns, releasing emotional blocks, and enhancing resilience.
Unlike standard antidepressants, which mask symptoms, psychedelics offer deep, transformational healing by addressing the root cause of depression.
Reunion’s clinical trial is testing whether a single psychedelic experience with RE 104 can significantly reduce postpartum depression symptoms.
✍️ Key Takeaways from the Q&A with Reunion Neuroscience:
✅ RE 104 is designed to be a fast, effective alternative to traditional antidepressants.
✅ Two doses are being tested—a low dose (5mg) and a high dose (30mg), with the latter producing a full psychedelic experience similar to a 25mg dose of psilocybin.
✅ The study is currently recruiting moms ages 18-45 who have given birth in the last 15 months and are experiencing postpartum depression.
✅ Breastfeeding moms are currently excluded, but Reunion is conducting a separate breast milk safety study to explore future options.
✅ Moms in the study will receive full support, including caregiver compensation, travel reimbursement, and expert monitoring throughout the process.
✅ Participation is FREE—and research sites are available across the U.S. (yes, even in Hawaii!).
🌟 How to Get Involved
If you—or someone you know—are struggling with postpartum depression and are curious about participating in the study, you can apply here.
💡 This research is mission-aligned with Moms on Mushrooms. While I’m not directly involved in the study, I believe in safe, intentional psychedelic use for women’s healing. Studies like this bring us closer to legitimizing alternative mental health treatments and making them accessible to more moms.
At the end of the day, healthy, happy moms raise healthy, happy kids. And if psychedelics can help us get there? Then it’s time we start talking about it.
👉 Share this with a mama who needs to hear it. Let’s spread the word and support this incredible research!
*Disclaimer:
Moms on Mushrooms (M.O.M.) is excited to share information about the RECONNECT Study in collaboration with Reunion Neuroscience, offering mothers experiencing postpartum depression a chance to explore innovative research opportunities. Please note that M.O.M. is not involved in conducting the study, and we are not responsible for its outcomes, safety, or results. Participation in the RECONNECT Study is entirely voluntary, and all medical, psychological, and safety concerns should be addressed directly with the study coordinators or your healthcare provider. Always consult a qualified medical professional before making decisions regarding your mental health or participation in clinical research.
To the fullest extent permitted by federal law and the laws of the following states—Alabama, Arizona, California, Colorado, Florida, Georgia, Hawaii, Kansas, Louisiana, Maryland, Massachusetts, Michigan, New Mexico, New York, North Carolina, Ohio, Pennsylvania, Texas, Utah, Virginia, and Wisconsin—M.O.M., including its directors, officers, employees, and agents, expressly disclaims any and all liability for any direct, indirect, incidental, consequential, or punitive damages (or any other loss or liability) arising out of or in connection with your reliance on the information provided or your participation in the study. By accessing this information, you acknowledge that you are participating at your own risk and agree to hold M.O.M. harmless from any and all claims related to the study.
Kommentarer